Healthcare >> CEO Interviews >> November 3, 1997
ALISON TAUNTON-RIBGY, PhD, is President and Chief Executive Officer of
Aquilia Biopharmaceuticals, Inc. (formerly Cambridge Biotech
Corporation), a public biotechnology company based in Worcester,
Massachusetts. Aquilia is a biopharmaceutical company involved in
developing and commercializing products for the treatment and prevention
of infectious diseases and cancer in humans and animals. Dr. Taunton-
Rigby is a Director and past President of the Massachusetts
Biotechnology Council (MBC), the trade organization representing
Massachusetts biotechnology companies, and a member of the Board of
Directors of BIO, the national trade organization, and Chair of BIO's
Emerging Companies Section. Dr. Taunton-Rigby has held senior management
positions at several biotech companies. Dr. Taunton-Rigby was Senior
Vice President, Biotherapeutics, of Genzyme Corporation, where she has
overall responsibility for Genzyme's biotherapeutics division.
Dr.Taunton-Rigby has also served in senior management positions at
several different biotechnology companies, including Mitotix, Inc.,
Vivotech, Biogen, Inc. and Collaborative Research Inc., and has also
worked in the Health Industries section at the consulting firm Arthur D.
Little. Dr. Taunton-Rigby received her Doctorate in Chemistry from the
University of Bristol in England and is a graduate of the Advanced
Management Program of the Harvard Business School. She is a Director of
Synaptic Pharmaceutical, Inc. and of the CML Group, a Trustee of the
Worcester Foundation for Biomedical Research and of the Committee for
Economic Development and a member of Bentley College Ethics Board. Profile
organization and the mission of Aquila Biopharmaceuticals?
Dr. Taunton-Rigby: Aquila is a product development company and
